» Authors » Matteo Cassandri

Matteo Cassandri

Explore the profile of Matteo Cassandri including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 504
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Perrone C, Pomella S, Cassandri M, Pezzella M, Giuliani S, Gasperi T, et al.
Front Cell Dev Biol . 2023 Feb; 11:1061570. PMID: 36755974
Rhabdomyosarcoma (RMS) is a pediatric myogenic soft tissue sarcoma that includes fusion-positive (FP) and fusion-negative (FN) molecular subtypes. FP-RMS expresses PAX3-FOXO1 fusion protein and often shows dismal prognosis. FN-RMS shows...
12.
Vaccaro S, Rossetti A, Porrazzo A, Camero S, Cassandri M, Pomella S, et al.
Front Pharmacol . 2022 Dec; 13:1071176. PMID: 36532747
Treatment of rhabdomyosarcoma (RMS), the most common a soft tissue sarcoma in childhood, provides intensive multimodal therapy, with radiotherapy (RT) playing a critical role for local tumor control. However, since...
13.
Pomella S, Porrazzo A, Cassandri M, Camero S, Codenotti S, Milazzo L, et al.
Int J Mol Sci . 2022 Nov; 23(21). PMID: 36362070
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence that includes FP-RMS, harboring the fusion oncoprotein PAX3/7-FOXO1 and FN-RMS, often mutant in the RAS pathway. Risk...
14.
Camero S, Cassandri M, Pomella S, Milazzo L, Vulcano F, Porrazzo A, et al.
Front Oncol . 2022 Oct; 12:1016894. PMID: 36248991
Management of rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, frequently accounting the genitourinary tract is complex and requires a multimodal therapy. In particular, as a consequence of...
15.
Codenotti S, Zizioli D, Mignani L, Rezzola S, Tabellini G, Parolini S, et al.
Cells . 2022 Sep; 11(18). PMID: 36139434
In pediatric rhabdomyosarcoma (RMS), elevated Akt signaling is associated with increased malignancy. Here, we report that expression of a constitutively active, myristoylated form of Akt1 (myrAkt1) in human RMS RD...
16.
Perrone C, Pomella S, Cassandri M, Pezzella M, Milano G, Colletti M, et al.
Front Oncol . 2022 May; 12:835642. PMID: 35574376
Rhabdomyosarcoma (RMS) is a pediatric myogenic soft tissue sarcoma. The Fusion-Positive (FP) subtype expresses the chimeric protein PAX3-FOXO1 (P3F) while the Fusion-Negative (FN) is devoid of any gene translocation. FP-RMS...
17.
Menna M, Fiorentino F, Marrocco B, Lucidi A, Tomassi S, Cilli D, et al.
Eur J Med Chem . 2022 May; 237:114410. PMID: 35525212
LSD1 is a histone lysine demethylase proposed as therapeutic target in cancer. Chemical modifications applied at C2, C4 and/or C7 positions of the quinazoline core of the previously reported dual...
18.
Pomella S, Cassandri M, Braghini M, Marampon F, Alisi A, Rota R
Int J Mol Sci . 2022 Feb; 23(4). PMID: 35216114
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase over-expressed and activated in both adult and pediatric cancers, where it plays important roles in the regulation of pathogenesis and progression...
19.
Camero S, Vitali G, Pontecorvi P, Ceccarelli S, Anastasiadou E, Cicchetti F, et al.
Cells . 2021 Nov; 10(11). PMID: 34831178
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood. Recently, we demonstrated the overexpression of both DNA methyltransferase 3A (DNMT3A) and 3B (DNMT3B) in RMS tumour biopsies and...
20.
Cassandri M, Pomella S, Rossetti A, Petragnano F, Milazzo L, Vulcano F, et al.
Int J Mol Sci . 2021 Oct; 22(19). PMID: 34639012
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. About 25% of RMS expresses fusion oncoproteins such as PAX3/PAX7-FOXO1 (fusion-positive, FP) while fusion-negative (FN)-RMS harbors RAS mutations. Radiotherapy...